Chemoinformatics is a major discipline in theoretical chemistry, using artificial intelligence and data sciences to tackle the current social and innovation challenges. Chemoinformatics concerns the development, creation, organization, storage, dissemination, analysis, visualization and use of chemical information. As a Chemistry discipline, it is rooted into experimental skills, on which are based the essential expertise for data acquisition, processing and modelling, to solve chemical problems and innovate in chemistry with the help of chemoinformatics techniques.The ChEMoinformaticsplus project describes an EMJM about Chemoinformatics, proposed by a consortium of eight academic sites: the University of Strasbourg (France), the University of Paris (France), the University NOVA of Lisbon (Portugal), the University of Milan (Italy), the University of Ljubljana (Slovenia), the University of Bar Ilan (Israel) and the Taras Shevchenko National University of Kiyv (Ukraine). The project federates an existing network of double diplomas in Chemoinformatics into a joint master program. Through this proposal, the consortium aims at increasing the number of students in this international program while improving scientific excellence and employability of the graduates. The consortium expects also, from the support of the European Commission, a gain of recognition and visibility for the scientific community in Chemoinformatics. Finally, this will give us the opportunity to restructure the network, enhance specialization of the different partners and increase our capacity to answer to future innovation challenges.

Multidrug resistance of Mycobacterium tuberculosis is declared a serious global threat by the World Health Organization. Our project aims at developing a comprehensive model of molecular mechanisms responsible for antimicrobial drug resistance of tuberculosis. Isoniazid is the main drug used for TB treatment, because it interacts with the bacterial catalase that leads to the bacterial death. The library of isoniazid resistant strains (over 100 different strains) will be used as experimental basis for building theoretical and computational models of the molecular processes leading to drug resistance of mutated bacteria. The model will be used for suggesting effective treatment targeting these mechanisms and overcoming the resistance. AMR-TB RISE will be used to utilise the expertise of highly specialised research groups of biologists, clinicians, biochemists, physicists, computer engineers, and mathematicians allowing the researches from these groups to work in multiple laboratories of the Consortium all over the world. Particular attention will be given to training the next generation of young researcher and forming tightly interconnected, long term collaboration devoted to solving the pressing global problem of antimicrobial resistance not only in TB, but in a wide spectrum of diseases.

Today, RW is mostly conceived as an arrangement enabling flexible work organization. However, REMAKING contends that RW can be more than that. If the multiple effects induced by RW on individuals, business models and the socio-economic sphere are properly understood and addressed by policymakers, it might become a lever contributing to shaping ongoing social, economic, and spatial structural changes. At the basis of REMAKING there is a profound consideration of the ongoing megatrends (i.e., digital transformation, flexibilization of production models) that have initiated RW and of the recent shocks (i.e., the pandemic and Russia’s war in Ukraine) that have consolidated the diffusion of different forms of RW. Through this angle, the multiple effects induced by RW call for rigorous analyses to support decision-makers in balancing opportunities and problems linked to RW for a potential rethinking of territories, namely in rural areas. REMAKING aims at delivering a policy-oriented framework reflecting the new and multi-faceted realities of RW, facilitating policymakers to adopt place-based policies balancing the opportunities and risks of RW and sharing practices to foster mutual learning on RW in the novel scenario of megatrends and shocks. These objectives will be achieved through participatory research activities across 4 case studies, each addressing a different form of RW (digital nomadism, post-pandemic, high-skilled in hi-tech sectors and enforced remote workers). The 4 case studies encompass overall 7 countries(Italy, Greece, Portugal, Germany, Czech Republic, Ukraine, Ireland): for each country, 1 second-tier city and 1 rural area will be studied. REMAKING generates an impact on socio-spatial transformation processes across second-tier cities and rural areas in terms of improved planning, design and implementation of multi-level policy, promotion of territorial socio-economic resilience and development, and advanced understanding of RW multiple impacts.

The overall / general objective of this proposal is to increase innovation potential and innovation management skills within SMEs in the all regions of Ukraine and to assist SMEs with potential for international growth via product, process, service or business model support. The project will follow a defined methodology to help regional businesses to increase their innovation capacity, to innovate profitably and also to successfully implement their innovative ideas on the competitive market. The EEN-Ukraine Consortium intends to enhance innovation capacity of SMEs by encouragement their participation in Horizon 2020 projects and provision of key account manager services to SMEs which implement H2020 SME Instrument projects. The secondary target group will be R&D organisations that will benefit from EEN services as well. The specific objectives for reaching the overall / general objective are as follows: - promote and support SMEs from Ukraine in participation on the H2020 SME Instrument and other H2020 programmes; - identify weaknesses in the innovation capacities of the beneficiary that hinder the realization of growth opportunities and of the full commercial potential of SME Instrument participants; - identify suitable coaches to address the identified weaknesses and moderating the coach-client relationship; - increase the innovation potential of SMEs lacking professional support in the field of innovation management; - help SMEs to select the most appropriate coach; - explain and sell the benefits of the SME Instrument's coaching service to potential beneficiaries; - facilitate the SME- coach relationship and ensure the effective teamwork and co-operation between the SME; - secure close cooperation links between the Consortium and the H2020 National Contact Point, regional stakeholders and other business and research support institutions; - accompany the beneficiary through the SME instrument project; - make the innovation system of Ukrainian SME more effective.

Project LIGHTHER (LIGHt-boosted THERapy) focuses on basic studies and early preclinical development of a groundbreaking therapy for one of the deadliest human diseases - lung cancer. The therapy includes in-patient activation of the immune system by light-controllable cytotoxic peptides, ex vivo loading of the patient’s dendritic cells (DCs) with exosomes or cancer cell lysates obtained using the same peptides, and treatment of the patients with the loaded DCs. Optimisation of efficacy and safety planned as the main outcome of the Project will pave the way for future preclinical and clinical studies of a radically novel, photosensitive drug. The main impact of the LIGHTHER Project in the long run will be creating a market segment for photopharmacology-based therapies. The participating institutions are complementary in their expertise, which will be transferred between them through secondments, research, and training. Lumobiotics, a small and medium enterprise (SME) with experience in drug development, will coordinate the work; Karlsruhe Institute of Technology and Taras Shevchenko National University of Kyiv will focus on the preparation and analysis of the peptides; National Cancer Institute of Ukraine will contribute its expertise in DC-based immunotherapy; SME Bienta and Amsterdam University Medical Center will do the in vitro and in vivo preclinical research. Six work packages are planned: 1) investigation of the immunogenic potential of light-controllable peptides; 2) evaluation of safety of the treatment by light-controllable peptides; 3) study of the DC activation by cancer cells treated by light-controllable peptides; 4) in vivo testing of the combination therapy on a lung cancer rodent model; 5) synthesis, laboratory scale peptide production, and analytics; 6) communication, dissemination, and management. The participating institutions will collaborate toward advancing the therapy to clinical applications, during the Project and after its completion.